PMID- 34804012 OWN - NLM STAT- MEDLINE DCOM- 20220107 LR - 20240509 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 12 DP - 2021 TI - Loss of Diacylglycerol Kinase alpha Enhances Macrophage Responsiveness. PG - 722469 LID - 10.3389/fimmu.2021.722469 [doi] LID - 722469 AB - The diacylglycerol kinases (DGKs) are a family of enzymes responsible for the conversion of diacylglycerol (DAG) to phosphatidic acid (PA). In addition to their primary function in lipid metabolism, DGKs have recently been identified as potential therapeutic targets in multiple cancers, including glioblastoma (GBM) and melanoma. Aside from its tumorigenic properties, DGKalpha is also a known promoter of T-cell anergy, supporting a role as a recently-recognized T cell checkpoint. In fact, the only significant phenotype previously observed in Dgka knockout (KO) mice is the enhancement of T-cell activity. Herein we reveal a novel, macrophage-specific, immune-regulatory function of DGKalpha. In bone marrow-derived macrophages (BMDMs) cultured from wild-type (WT) and KO mice, we observed increased responsiveness of KO macrophages to diverse stimuli that yield different phenotypes, including LPS, IL-4, and the chemoattractant MCP-1. Knockdown (KD) of Dgka in a murine macrophage cell line resulted in similar increased responsiveness. Demonstrating in vivo relevance, we observed significantly smaller wounds in Dgka(-/-) mice with full-thickness cutaneous burns, a complex wound healing process in which macrophages play a key role. The burned area also demonstrated increased numbers of macrophages. In a cortical stab wound model, Dgka(-/-) brains show increased Iba1(+) cell numbers at the needle track versus that in WT brains. Taken together, these findings identify a novel immune-regulatory checkpoint function of DGKalpha in macrophages with potential implications for wound healing, cancer therapy, and other settings. CI - Copyright (c) 2021 Manigat, Granade, Taori, Miller, Vass, Zhong, Harris and Purow. FAU - Manigat, Laryssa C AU - Manigat LC AD - Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States. FAU - Granade, Mitchell E AU - Granade ME AD - Department of Pharmacology, School of Medicine, University of Virginia, Charlottesville, VA, United States. FAU - Taori, Suchet AU - Taori S AD - Department of Neurology, Division of Neuro-Oncology, University of Virginia, Charlottesville, VA, United States. FAU - Miller, Charlotte Anne AU - Miller CA AD - Department of Neurology, Division of Neuro-Oncology, University of Virginia, Charlottesville, VA, United States. FAU - Vass, Luke R AU - Vass LR AD - Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States. FAU - Zhong, Xiao-Ping AU - Zhong XP AD - Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC, United States. FAU - Harris, Thurl E AU - Harris TE AD - Department of Pharmacology, School of Medicine, University of Virginia, Charlottesville, VA, United States. FAU - Purow, Benjamin W AU - Purow BW AD - Department of Neurology, Division of Neuro-Oncology, University of Virginia, Charlottesville, VA, United States. LA - eng GR - P30 CA044579/CA/NCI NIH HHS/United States GR - R01 CA180699/CA/NCI NIH HHS/United States GR - R01 CA189524/CA/NCI NIH HHS/United States GR - R01 GM136900/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20211105 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - EC 2.7.1.107 (Diacylglycerol Kinase) SB - IM MH - Animals MH - Diacylglycerol Kinase/genetics/*metabolism MH - Disease Models, Animal MH - Macrophages/*metabolism MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Neoplasms/metabolism MH - T-Lymphocytes/*cytology/immunology PMC - PMC8603347 OTO - NOTNLM OT - BMDM OT - DGKalpha OT - diacylglycerol kinase OT - immune regulation OT - macrophage OT - wound healing COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/11/23 06:00 MHDA- 2022/01/08 06:00 PMCR- 2021/01/01 CRDT- 2021/11/22 06:41 PHST- 2021/06/08 00:00 [received] PHST- 2021/10/21 00:00 [accepted] PHST- 2021/11/22 06:41 [entrez] PHST- 2021/11/23 06:00 [pubmed] PHST- 2022/01/08 06:00 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2021.722469 [doi] PST - epublish SO - Front Immunol. 2021 Nov 5;12:722469. doi: 10.3389/fimmu.2021.722469. eCollection 2021.